OncoArray: Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI)

The Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) was one of five projects funded in 2010 as part of the NCI's Genetic Associations and Mechanisms in Oncology (GAME-ON) initiative (http://epi.grants.cancer.gov/gameon/). FOCI represents a collective effort that builds upon the strengths and history of collaboration inherent in the Ovarian Cancer Association Consortium (OCAC), a multidisciplinary group comprised of epidemiologists, genetic epidemiologists, statistical geneticists, molecular and cell biologists and clinicians that was formed in 2005. The other four funded GAME-ON projects were: the ColoRectal TransdisciplinaryStudy (CORECT), Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE), Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE), and Transdisciplinary Research in Cancer of the Lung (TRICL).

As part of our aim to discover, expand, and replicate ovarian cancer susceptibility loci, the GAME-ON projects and other consortia formed the OncoArray network (http://epi.grants.cancer.gov/oncoarray/) to develop and genotype a new custom genotyping array in large numbers of cancer cases and controls (over 400,000 samples) across multiple cancer types. The FOCI data includes over 50,000 ovarian cancer cases and controls genotyped with the Oncoarray at the Center for Inherited Disease Research (CIDR). Genotype calling and quality control procedures were performed under a standardized protocol across the Oncoarray consortium, and over 490,000 SNPs passed QC and are included under this dbGaP submission.

• Study Weblinks:
  • OncoArray Network
• Study Design:
  • Case-Control
• Study Type:
  • Case-Control
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 50315
• Subject Sample Telemetry Report (SSTR)

• BioProject
• PubMed
• MeSH
• PMC

This project includes study participants from 56 studies from the Ovarian Cancer Association Consortium (OCAC) that collaborated in the OncoArray project. Individual study details have been published and a full list of studies is provided on the OCAC website (http://ocac.ccge.medschl.cam.ac.uk/). All participants provided written informed consent and each contributing study was approved by the relevant local institutional research ethics committee. Cases were diagnosed with primary invasive ovarian, fallopian tube, or peritoneal epithelial cancer. Controls were unaffected women with at least one intact ovary.

• Primary Phenotype: Carcinoma, Ovarian Epithelial
• Genital Neoplasms, Female
• Genome-Wide Association Study

• Principal Investigator
  • Thomas A. Sellers, PhD. Moffitt Cancer Center, Tampa, FL, USA.
• Funding Sources
  • U19-CA148112. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • R01-CA149429. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • R01-CA058598. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • CA1X01HG007491-01. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• Genotyping Center
  • Center for Inherited Disease Research (CIDR). Johns Hopkins University, Baltimore, MD, USA.
• Funding Source for CIDR Genotyping
  • HHSN268201200008I. NIH contract "High throughput genotyping for studying the genetic contributions to human disease". National Institutes of Health, Bethesda, MD, USA.